BioSpace News Archive

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine in Canada.

ANI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the Company’s supplemental New Drug Application for Purified Cortrophin™ Gel for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis and rheumatoid arthritis, in addition to excess urinary protein due to nephrotic syndrome.

Helius Medical Technologies, Inc. today announced that the Company will release its third quarter 2021 financial results on Wednesday, November 10, 2021, after the market closes.

Algernon Pharmaceuticals Inc. is pleased to announce that it has established the optimum peak stimulation period of 6 hours for neuron outgrowth by AP-188 (“N,N-Dimethyltryptamine” or “DMT”) in its pre-clinical in vitro study conducted by Charles River Laboratories.

Cabaletta Bio, Inc. today reported financial results for the third quarter ended September 30, 2021, and provided a business update.

EyePoint Pharmaceuticals, Inc. today announced the appointment of Jay S. Duker, M.D. as Chief Operating Officer (COO).

Akouos, Inc. today announced the appointment of Stacy Price as chief technical officer.

TELA Bio, Inc. today announced it has entered into a distribution agreement with Next Science granting TELA exclusive rights to sell and market Next Science’s proprietary antimicrobial surgical wash with XBIO ® technology.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the presentation of preclinical data from a series of internally developed dual agonists of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors at ObesityWeek® 2021.